Somatostatin analogs in oncology: A look to the future

Chemotherapy

Volumn 47, Issue SUPPL. 2, 2001, Pages 162-196

  Jenkins, Spencer A ^a,b   Kynaston, Howard G ^b   Davies, Nick ^c   Baxter, John N ^a   Nott, David M ^d  

^a MORRISTON HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Neoplasms; Review; Somatostatin analogs; Therapy

Indexed keywords

ANGIOPEPTIN; AROMATASE INHIBITOR; CYTOTOXIC AGENT; IMMUNOMODULATING AGENT; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TAMOXIFEN; VAPREOTIDE;

ACROMEGALY; ADVANCED CANCER; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DESENSITIZATION; DRUG EFFICACY; GASTROINTESTINAL TUMOR; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; FORECASTING; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; SOMATOSTATIN;

EID: 0035078037     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049168     Document Type: Review

References (143)

1. Stimulated and inhibitory effects of purified hypothalmic extracts on growth hormone release from the rat pituitary in vivo
2. Hypothalmic peptide that inhibits the secretion of immunoreactive pituitary growth hormone
3. Somatostatin: Total solid phase synthesis
4. Gastrointestinal cells producing endocrine, neueuroendocrine and paracrine messengers
5. Central nervous system effects of hypothalmic peptides
6. Somatostatin inhibits adrenergic and cholinergic neurotransmission in smooth muscle
7. Somatostatin: Interaction with the sympathetic nervous system in guinea pigs
8. Inhibition of growth hormone and thyrotropin release by growth release inhibiting hormone
9. Metabolic clearance and plasma half-life disappearance time of endogenous somatostatin in man
10. Somatostatin analogues: Clinical application in relation to human somatostatin receptor subtypes
11. Therapeutic potential of octreotide in the treatment of liver metastases
12. The elucidation of somatostatin receptor functions: A current view
13. Mechanisms of antineoplastic action of somatostatin analogues
14. Antiproliferative effect of somatostatin and analogs
15. Molecular pharmacology of somatostatin receptor subtypes
16. The somatostatin receptor family
17. Octreotide and nonendocrine tumours. Basic knowledge and therapeutic potential
18. Somatostatin binding in human gastrointestinal tissues: Effects of cations and somatostatin analogues
19. Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications
20. Prognostic value of receptors for the insulin like growth factor 1, somatostatin and epidermal growth factor in human breast cancer
21. Point mutation of the somatostatin receptor 2 gene in human small cell lung cancer cell line COR-L103
22. Heterogenous expression of two somatostatin receptor subtypes in pituitary tumours
23. Expression of three somatostatin receptor analogues on pituitary adenomas. Evidence for preferential sstr5 expression in the mammosomatograph lineage
24. Identification of somatostatin receptors subtypes and an implication of the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumours
25. Expression of mRNA for all five human somatostatin receptors (hsstr1-5) in pituitary tumours
26. Somatostatin receptor subtype gene expression in pituitary adenomas
27. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumours and renal cell carcinoma
28. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues by human receptors subtypes sstr1 and sstr2
29. Inhibition of cell proliferation by the somatostatin analogue RC-160 mediated by somatostatin receptor subtypes SSTR and SSTR5 through different mechanisms
30. Octapeptide somatostatin analogue SMS 201-995 induces translocation of intracellular PTPIC to membranes in MCF-7 human breast adenocarcinoma cells
31. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cells
32. Somatostatin receptor (sstr) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumours
33. Human kidney as a target for somatostatin: High affinity receptors in tubules and vasa recta
34. Different expression patterns of somatostatin receptor subtypes in cultured cells from human normal and prostate cancer
35. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogues on hormone release in a small group of pituitary and islet cell tumours
36. Somatostatin and somatostatin receptor subtype expression in medullary thyroid carcinoma
37. Expression of somatostatin receptor subtype messenger RNA in human colonic cancers and normal mucosa
38. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumour host interaction
39. Local up-regulation of neuropeptide receptors in host blood vessels around human colorectal cancers
40. Lack of cross-desensitisation of somatostatin-14 and somatostatin-28 receptors coupled to potassium channels in rat neocortical neurones
41. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one week administration
42. Inhibition of pancreatic secretion under long-term octreotide treatment in humans
43. Relationship between receptor binding and biopotency of somatostatin-14 and somatostatin-28 in mouse pituitary tumour cells
44. Somatostatin pretreatment increases the number of somatostatin receptors on GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin
45. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160
46. Somatostatin regulates somatostatin receptor subtype mRNA expression in GH3 cells
47. Internalisation of the radioiodinated somatostatin analogue [125I-Tyr3]OCTREOTIDE by mouse and human pituitary tumour cells. Increase by unlabelled octreotide
48. Somatostatin analogues: Mechanism of action
49. Molecular properties of somatostatin receptors
50. Molecular biology of somatostatin receptor subtypes
51. Molecular pharmacology of somatostatin receptors
52. The elucidation of somatostatin receptor functions; a current view
53. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture
54. Mechanism of thyroid hormone stimulation of thyrotropin-releasing hormone action
55. Characterisation of 17-beta-estradiol-dependant and -independent somatostatin receptor subtypes in rat anterior pituitary
56. Somatostatin receptor manipulation
57. Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin
58. Direct inhibitory effects of somatostatin analogues on the growth of human breast cancer cells
59. A dual effect of somatostatin on the proliferation of cultured rat mesangial cells
60. Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cells
61. Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth
62. Somatostatin analogues affect proliferation of human thyroid carcinoma cell lines in vitro
63. Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma
64. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
65. Intermittent androgen deprivation after PSA - Complete response as a strategy to reduce induction of hormone-resistant prostate cancer
66. Prospective study of somatostatin receptor scintigraphy and its operative outcome in patients with Zollinger-Ellison syndrome
67. Positon emission tomography with 5 hydroxytryptophan in neuroendocrine tumours
68. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma
69. Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumours of the liver
70. Metastatic endocrine tumours: Is there a place for liver transplantation?
71. Liver transplantation for metastatic neuroendocrine tumours
72. Results of liver transplantation in the treatment of metastatic neuroendocrine tumours. A 31 case French multicentre study
73. Octreotide acetate (Sandostatin) increases in vivo accumulation of doxirubicin
74. SMS 201-995 inhibits the growth of liver metastases from colorectal cancer and increase in vitro toxicity of fluorouracil
75. Potentiation of the anti-proliferative effects of anti cancer drugs by octreotide in vivo and in vitro
76. Improving the quality of reporting of randomised controlled trials: The consort statement
77. Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study
78. Cytotoxic and hormonal treatment for metastatic breast cancer: A systemic review of published randomised trials involving 31,500 women
79. Cytotoxic analogue of somatostatin containing methotrexate inhibits growth of MIA PaCA-2 human pancreatic xenografts in nude mice
80. Synthesis and biological evaluation of cyto-toxic analogues of somatostatin containing doxorubicin and its potent derivative 2-pyrrolinodoxorubicin
81. Liver metastases from colorectal cancer: Lessons from past and present clinical studies
82. Pancreatic cancer: Does octreotide offer any promise?
83. GI cancer refractory to chemotherapy: A room for octreotide
84. Resection of the liver for colorectal metastases: A multi-institutional study of patterns of recurrence
85. Resection of colorectal liver metastases
86. Indicators of prognosis after hepatic resection for colorectal secondaries
87. Treatment of colorectal liver metastases
88. The enhancement of tumour growth after partial hepatectomy and the effect of sera obtained from hepatectomised rats on tumour cell growth
89. Facilitation by partial hepatectomy of tumour growth within the rat liver following intraportal injection of syngeneic tumour cells
90. Effects of octreotide on liver regeneration and tumour growth in the regenerating liver
91. Octreotide in the management of hormone-refractory prostate cancer
92. A randomised trial of tamoxifen alone or combined with octreotide in the treatment of metastastic breast carcinoma
93. A phase 3 trial of octreotide pamoate (op lar) and tamoxifen versus placebo and tamoxifen in metastatic breast cancer
94. Octreotide as a first-line treatment for women with metastatic breast cancer
95. The effect of a long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer
96. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells
97. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells
98. Enhancement of tamoxifen-induced suppression of insulin-like growth factor, gene expression and serum level by a somatostatin analogue
99. Effect of tamoxifen on serum insulin-like growth factor 1 levels in stage 1 breast cancer patients
100. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(α)anthracene-induced rat mammary carcinomas
101. The relationship between somatostatin, epidermal growth factor and steroid hormone receptors in breast cancer
102. Feasibility, endocrine and antitumour effects of a triple therapy with tamoxifen, a somatostatin analogue and an antiprolactin in postmenopausal metastatic breast cancer: A randomised study with long-term follow-up
103. Tamoxifen for early breast cancer: An overview of the randomised trials
104. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostate cancer
105. Low dose of octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas
106. Octreotide combined with gorserelin in the therapy of advanced pancreatic cancer - Results of pilot study and review of the literature
107. The host-tumour immune conflict from immunosuppression to resistance and destruction
108. Immunosuppressive effect of surgery
109. Effects of operation on immune response in cancer patients: Sequential evaluation of in vitro lymphocyte function
110. Suppression of cellular immunity by anaesthesia, by surgery and operation
111. Changes in human natural killer cell activity early and late after renal transplantation using conventional immunosuppression
112. The influence of surgical operations on components of the human immune system
113. Immune function in patients undergoing open versus laparoscopic cholecystectomy
114. Monocyte activation after open and laparoscopic surgery
115. Murine tumour cells metastasising selectively in the liver: Ability to produce hepatocyte-activating cytokines interleukin-1 and -6
116. The development of new immunotherapies for the treatment of cancer using interleukin-2
117. Cytokine tumour cell death and immunogenicity: A question of choice
118. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer
119. Immunoneuroendocrine therapy for endocrine tumours: Recent developments
120. Octreotide and interferon-alpha: A new combination for the treatment of malignant carcinoid tumours
121. Dramatic response of metastatic carcinoid to a combination of interferon and octreotide
122. Somatostatin and the immune and haematopoietic system: A review
123. Effect of pentoxifylline and somatostatin on tumour necrosis factor production by human pulmonary macrophages
124. Somatostatin and VIP reduce interferon production in human peripheral mononuclear cells
125. Inhibitory effects of somatostatin and some analogues on human natural killer cell activity
126. Therapy of neurometastatic tumours with radiolabelled MIBG and somatostatin analogues
127. Preclinical experience with Rb-188-RC-160, a radiolabelled somatostatin analogue for use in peptide-targeted radiotherapy
128. The next frontier of molecular medicine: Delivery of therapeutics
129. Effects of octreotide on angiogenesis
130. Somatostatin analogues: Angiogenesis inhibitors with novel mechanisms of action
131. Endostatin: An endogenous inhibitor of angiogenesis and tumour growth
132. Angiostatin induces and sustains dormancy of human primary tumours in mice
133. Angiostatin gene transfer: Inhibition of tumour growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
134. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie 2
135. Gene therapy for cancer: What have we done and where are we going?
136. Induction of apoptosis in rat hepatocarcinoma cells by expression of 1GF-1 antisense c-DNA
137. Database of p53 gene somatic mutations in human tumours and cell lines
138. Therapeutic effect of a wild type p53-expression vector in an orthotopic lung cancer model
139. In vivo adenovirus mediated p53 tumour supressor gene therapy for colorectal cancer
140. Novel combination therapy for human colon cancer with adenovirus-mediated wild type p53 gene transfer and DNA-damaging chemotherapeutic agents
141. Amplification of a gene encoding a p53-associated protein in human sarcomas
142. Subtype specific induction of wild type p53 and apoptosis, but not cell cycle arrest by human somatostatin receptor 3